Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Franco, Juan Víctor Ariel; Turk, Tarek; Jung, Jae Hung; Xiao, Yu‐Tian; Iakhno, Stanislav; Tirapegui, Federico Ignacio; Garrote, Virginia; Vietto, Valeria

doi:10.1002/14651858.cd012552.pub2

Cited by 54 publications

(69 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This systematic review and meta‐analysis was based on a published protocol , performing comprehensive searches in July 2019 in the Cochrane Central Register of Controlled Trials, the Medical Literature Analysis and Retrieval System Online (MEDLINE) Ovid, the Excerpta Medica dataBASE (EMBASE), PsycINFO Ovid, Cumulative Index to Nursing and Allied Health Literature (CINAHL) Elton B. Stephens Co. (EBSCO), http://ClinicalTrials.gov, International Standard Randomised Controlled Trial Number (ISRCTN) Registry, WHO International Clinical Trials Registry Platform (ICTRP), among other resources. Review authors working in pairs independently screened all potentially relevant records and classified studies in accordance with the criteria for each provided in the Cochrane Handbook for Systematic Reviews of Interventions .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Patients and Methods We performed a comprehensive search using multiple databases, trial registries, grey literature and conference proceedings with no restrictions on the language of publication or publication status. The date of the latest search of all databases was July 2019. We included randomised controlled trials. Inclusion criteria were men with a diagnosis of CP/CPPS. We included all available pharmacological interventions. Two review authors independently classified studies and abstracted data from the included studies, performed statistical analyses and rated quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods. The primary outcomes were prostatitis symptoms and adverse events. The secondary outcomes were sexual dysfunction, urinary symptoms, quality of life, anxiety and depression. Results We included 99 unique studies in 9119 men with CP/CPPS, with assessments of 16 types of pharmacological interventions. Most of our comparisons included short‐term follow‐up information. The median age of the participants was 38 years. Most studies did not specify their funding sources; 21 studies reported funding from pharmaceutical companies. We found low‐ to very low‐quality evidence that α‐blockers may reduce prostatitis symptoms based on a reduction in National Institutes of Health – Chronic Prostatitis Symptom Index (NIH‐CPSI) scores of >2 (but <8) with an increased incidence of minor adverse events such as dizziness and hypotension. Moderate‐ to low‐quality evidence indicates that 5α‐reductase inhibitors, antibiotics, anti‐inflammatories, and phytotherapy probably cause a small decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse events. Intraprostatic botulinum toxin A (BTA) injection may cause a large reduction in prostatitis symptoms with procedure‐related adverse events (haematuria), but pelvic floor muscle BTA injection may not have the same effects (low‐quality evidence). Allopurinol may also be ineffective for reducing prostatitis symptoms (low‐quality evidence). We assessed a wide range of interventions involving traditional Chinese medicine; low‐quality evidence showed they may reduce prostatitis symptoms without an increased incidence in adverse events. Moderate‐ to high‐quality evidence indicates that the following interventions may be ineffective for the reduction of prostatitis symptoms: anticholinergics, Escherichia coli lysate (OM‐89), pentosan, and pregabalin. Low‐ to very low‐quality evidence indicates that antidepressants and tanezumab may be ineffective for the reduction of prostatitis symptoms. Low‐quality evidence indicates that mepartricin and phosphodiesterase inhibitors may reduce prostatitis symptoms, without an increased incidence in adverse events. Conclusions Based on the findings of low‐ to very low‐quality evidence, this review found that some pharmaco...

show abstract

Section: Methodsmentioning

confidence: 99%

“…This is an abridged version of a Cochrane review published in the Cochrane Library titled ‘Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome’ including a summary of its main comparisons. Our objective was to assess the effects of pharmacological therapies for CP/CPPS.…”

Section: Introductionmentioning

confidence: 99%

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…We performed head‐to‐head comparisons or intervention vs placebo or sham procedure/no treatment comparisons. We did not include studies evaluating only pharmacological interventions to avoid overlapping with the review ‘Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome’.…”

Section: Methodsmentioning

confidence: 99%

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

et al. 2019

Self Cite

View full text Add to dashboard Cite

Based on the findings of moderate to high-quality evidence, this review found that some non-pharmacological interventions such as acupuncture and extracorporeal shockwave therapy are likely to result in a decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse event. The QoE for most other comparisons was predominantly low. Future clinical trials should include a full report of their methods including adequate masking, consistent assessment of all patient-important outcomes including potential treatment-related adverse events and appropriate sample sizes. This article is protected by copyright. All rights reserved.

show abstract

“…TCM gives priority to the concept of holism in diagnosis and pays more attention to the overall changes in function. e treatment is based on syndrome differentiation, emphasizing the recovery of overall function, which is similar to the network concept of network pharmacology [52].…”

Section: Discussionmentioning

confidence: 99%

Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology

Tang

Wang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Polycystic ovary syndrome (PCOS) is the most common female endocrine disease. Cangfu Daotan Decoction (CDD) can effectively relieve the clinical symptoms of PCOS patients. Methods. To explore the active ingredients and related pathways of CDD for treating PCOS, a network pharmacology-based analysis was carried out. The active ingredients of CDD and their potential targets were obtained from the TCM system pharmacology analysis platform. The obtained PCOS-related genes from OMIM and GeneCards were imported to establish protein-protein interaction networks in STRING. Finally, GO analysis and significant pathway analysis were conducted with the RStudio (Bioconductor) database. Results. A total of 111 active compounds were obtained from 1433 ingredients present in the CDD, related to 118 protein targets. In addition, 736 genes were found to be closely related to PCOS, of which 44 overlapped with CDD and were thus considered therapeutically relevant. Pathway enrichment analysis identified the AGE-RAGE signalling pathway in diabetic complications, endocrine resistance, the IL-17 signalling pathway, the prolactin signalling pathway, and the HIF-1 signalling pathway. Moreover, PI3K-Akt, insulin resistance, Toll-like receptor, MAPK, and AGE-RAGE were related to PCOS and treatment. Conclusions. CDD can effectively improve the symptoms of PCOS, and our network pharmacological analysis lays the foundation for future clinical research.

show abstract

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Cited by 54 publications

References 181 publications

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology

Contact Info

Product

Resources

About